PROCEPT BioRobotics Corporation $PRCT Shares Purchased by Chicago Capital LLC

Chicago Capital LLC boosted its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 175.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,568,845 shares of the company’s stock after acquiring an additional 999,873 shares during the period. PROCEPT BioRobotics comprises about 1.4% of Chicago Capital LLC’s holdings, making the stock its 27th biggest holding. Chicago Capital LLC owned 2.82% of PROCEPT BioRobotics worth $55,992,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PRCT. Vega Investment Solutions increased its stake in shares of PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after purchasing an additional 265 shares in the last quarter. AlphaQuest LLC boosted its holdings in PROCEPT BioRobotics by 1,262.5% in the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after buying an additional 1,010 shares during the last quarter. CWM LLC increased its stake in PROCEPT BioRobotics by 40.7% during the 2nd quarter. CWM LLC now owns 1,228 shares of the company’s stock worth $71,000 after buying an additional 355 shares in the last quarter. Lazard Asset Management LLC raised its holdings in shares of PROCEPT BioRobotics by 90.7% during the second quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after acquiring an additional 810 shares during the last quarter. Finally, RiverPark Advisors LLC lifted its position in shares of PROCEPT BioRobotics by 22.5% in the second quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock valued at $101,000 after acquiring an additional 324 shares in the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on PRCT. UBS Group initiated coverage on PROCEPT BioRobotics in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 price target for the company. Wells Fargo & Company lowered their target price on shares of PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Morgan Stanley reduced their target price on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group raised shares of PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a research note on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.40.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock opened at $33.12 on Tuesday. The firm has a 50 day simple moving average of $32.54 and a 200-day simple moving average of $40.24. PROCEPT BioRobotics Corporation has a 1-year low of $27.80 and a 1-year high of $89.49. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -21.65 and a beta of 0.99.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. The firm had revenue of $83.33 million for the quarter, compared to analysts’ expectations of $80.78 million. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.40) earnings per share. On average, analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.